Implementation and outcomes of monoclonal antibody infusion for COVID-19 in an inner-city safety net hospital: A South-Bronx experience


Posted: 2021-09-15 19:00:00
Background: Monoclonal antibody therapy (MAT) is recommended in mild to moderate Coronavirus disease 2019 (COVID-19) patients who are at risk of progressing to severe disease. Due to limited data on its outcomes and the logistic challenges in administering the drug, MAT has not been widely used in the United States (US) despite of emergency use authorization (EUA) approval by the Food and Drug Administration (FDA). Aim: We aim to study the outcomes of MAT in patients predominantly from ethnic minority groups and the challenges we experienced in implementing the infusion therapy protocol in an inner-city safety-net-hospital in the South Bronx. Methods and results: We conducted a retrospective observational study of 49 patients who were offered MAT as per EUA protocol of FDA. Patient who met the criteria for MAT and received therapy were included in treatment group (n = 38) and the remaining (n = 11) who declined treatment were included in the control group. A majority of patients (76%) in the study group reported symptomatic improvement, the day after infusion. There was statistically significant reduction in COVID-19 related hospitalizations (7.8 vs 54.5%, P = < 0.001) mortality (0 vs 18.1%, P value = 0.008) in the treatment group. Conclusion: MAT reduced both hospitalization and mortality in this predominantly Hispanic patient population with mild to moderate COVID-19 with high risk factors for disease progression. Keywords: Bamlanivimab; Bamlanivimab-etesevimab; Casirivimab-imdevimab; Mild-moderate COVID-19; Mortality.

参考サイト PubMed: covid-19


Powered by Vergleichsportal


バイオクイックニュース日本語版:COVID-19特集

バイオクイックニュース日本語版
9月 06, 2021 バイオアソシエイツ

COVID-19ウイルスの広範な変異種から防御する抗体を発見。変異種間で変化の少ない受容体結合ドメイン(RBD)を標的としている。

現在のCOVID-19を引き起こすウイルスは、はるか昔の2019年12月に最初に人々を病気にしたウイルスと同じではない。現在流行している亜種の多くは、元のウイルスに基づいて開発された抗体ベースの治療薬の一部に部分的に耐性を持っている。パンデミックが続くと、必然的にさらに多くの亜種が発生し、耐性の問題は大きくなる一方だ。ワシントン大学医学部(セントルイス)の研究者らは、広範囲のウイルス亜種に対して低用量で高い保護効果を示す抗体を発見した。さらに、この抗体は、ウイルスの亜種間でほとんど違いのない部分に結合するため、この…